Seasonal influenza virus vaccine high-dose - Sanofi Pasteur

Drug Profile

Seasonal influenza virus vaccine high-dose - Sanofi Pasteur

Alternative Names: Fluzone HD; Fluzone® High Dose IM; Fluzone® High-Dose influenza vaccine; High-Dose Influenza Vaccine Quadrivalent; Seasonal influenza virus vaccine - sanofi pasteur

Latest Information Update: 12 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi K.K.; Sanofi Pasteur
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 21 Dec 2017 Registered for Influenza virus infections (Prevention, In the elderly) in Australia (IM)
  • 13 Dec 2017 Sanofi Pasteur and Sanofi K.K. completes a phase I/II immunogenicity trial for Influenza virus infections (Prevention, In the elderly, In volunteers) in Japan (IM) (SC) (NCT03233217)
  • 18 Sep 2017 Sanofi Pasteur completes enrolment in a phase III trial for Influenza virus infections (In the elderly, Prevention) in USA (NCT03282240)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top